Infections, Papillomavirus Clinical Trial
Official title:
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Verified date | October 2019 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is intended to provide up to a maximum of four years of annual oncogenic human
papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study
subjects who displayed normal cervical cytology but tested positive for oncogenic HPV
infection at their concluding NCT00294047 study visit.
Women who were pregnant at their concluding NCT00294047 study visit may also be included in
this study, as no cervical sample could be collected at that visit.
The objectives and outcome measures of the primary phase (NCT00294047) are presented in a
separate protocol posting.
Status | Completed |
Enrollment | 34 |
Est. completion date | September 20, 2017 |
Est. primary completion date | September 20, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 28 Years and older |
Eligibility |
Inclusion Criteria: - Written informed consent obtained from the subject prior to enrolment. - Subjects who the investigator believes that they can and will comply with the requirements of the protocol. - A subject previously enrolled in the study NCT00294047 and who fulfils either of the following criteria: - displayed normal cervical cytology but tested positive for oncogenic HPV infection at her concluding NCT00294047 study visit - was pregnant so that no cervical sample could be collected at her concluding NCT00294047 study visit Exclusion Criteria: - A subject who at the NCT00294047 concluding study visit displayed normal cervical cytology and who was negative for oncogenic HPV infection at that visit. - A subject who at the NCT00294047 concluding study visit had a cervical lesion at that visit or who had a cervical lesion that required treatment at her NCT00294047 exit colposcopy. - A subject for whom the cervical cytology results from the concluding NCT00294047 study visit were unavailable for reasons other than pregnancy. |
Country | Name | City | State |
---|---|---|---|
Canada | GSK Investigational Site | Edmonton | Alberta |
Canada | GSK Investigational Site | Halifax | Nova Scotia |
Canada | GSK Investigational Site | Sherbrooke | Quebec |
Canada | GSK Investigational Site | Truro | Nova Scotia |
Canada | GSK Investigational Site | Vancouver | British Columbia |
Netherlands | GSK Investigational Site | Amsterdam | |
Netherlands | GSK Investigational Site | Rotterdam | |
Portugal | GSK Investigational Site | Almada | |
Portugal | GSK Investigational Site | Coimbra | |
Portugal | GSK Investigational Site | Lisboa | |
Portugal | GSK Investigational Site | Setúbal | |
Russian Federation | GSK Investigational Site | Moscow | |
Russian Federation | GSK Investigational Site | Sankt-Petersburg | |
Singapore | GSK Investigational Site | Singapore | |
Singapore | GSK Investigational Site | Singapore | |
United Kingdom | GSK Investigational Site | London | |
United Kingdom | GSK Investigational Site | Manchester | |
United States | GSK Investigational Site | Iowa City | Iowa |
United States | GSK Investigational Site | Wenatchee | Washington |
United States | GSK Investigational Site | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States, Canada, Netherlands, Portugal, Russian Federation, Singapore, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 12 | Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. | At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 24 | Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. | At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 36 | Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. | At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 48 | Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. | At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 12 | Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium. |
At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 24 | Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium. |
At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 36 | Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium. |
At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 48 | Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium. |
At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Colposcopy at Month 12 | Detection was done on all subjects irrespective of their baseline HPV DNA status. | At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Colposcopy at Month 24 | Detection was done on all subjects irrespective of their baseline HPV DNA status. | At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Colposcopy at Month 36 | Detection was done on all subjects irrespective of their baseline HPV DNA status. | At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Colposcopy at Month 48 | Detection was done on all subjects irrespective of their baseline HPV DNA status. | At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Treatment at Month 12 | If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. | At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Treatment at Month 24 | If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. | At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Treatment at Month 36 | If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. | At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] | |
Primary | Number of Subjects With Referral to Treatment at Month 48 | If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. | At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01290393 -
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
|
||
Completed |
NCT00369824 -
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT00345878 -
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
|
Phase 3 | |
Completed |
NCT00947115 -
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT01187927 -
Drug Use Investigation for Cervarix®
|
N/A | |
Completed |
NCT00169494 -
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
|
Phase 3 | |
Completed |
NCT00359619 -
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
|
Phase 2 | |
Completed |
NCT00196937 -
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
|
Phase 3 | |
Completed |
NCT00534638 -
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
|
Phase 4 | |
Completed |
NCT00250276 -
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
|
Phase 3 | |
Completed |
NCT01031069 -
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
|
Phase 4 | |
Completed |
NCT00996125 -
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT00779766 -
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
|
Phase 3 | |
Completed |
NCT01953822 -
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
|
N/A | |
Completed |
NCT01153906 -
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
|
N/A | |
Completed |
NCT01207999 -
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
|
N/A | |
Completed |
NCT00693615 -
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
|
Phase 2 | |
Completed |
NCT00693966 -
Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females
|
Phase 2 | |
Completed |
NCT00541970 -
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
|
Phase 1 | |
Completed |
NCT01627561 -
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
|
Phase 3 |